CORRIGENDUM: Interim results of the first stage of a multicenter open multi-cohort study of the safety, pharmacokinetics, pharmacodynamics and efficacy of veranafusp alfa in adult patients with mucopolysaccharidosis type II. [Pharmacy & Pharmacology. 2026;14(1):81-96. DOI: 10.19163/2307-9266-2026-14-1-81-96]

Related to the article: Lukina E.A., Ponomarev R.V., Trishina S.V., Gabitova E.S., Vashakmadze N.D., Karkashadze G.A., Namazova-Baranova L.S. Interim results of the first stage of a multicenter open multi-cohort study of the safety, pharmacokinetics, pharmacodynamics and efficacy of veranafusp alfa in adult patients with mucopolysaccharidosis type II. Pharmacy & Pharmacology. 2026;14(1):81-96. https://doi.org/10.19163/2307-9266-2026-14-1-81-96

We hereby inform readers that changes have been made to the final version of the article in Russian.

In the published article “Interim results of the first stage of a multicenter open multi-cohort study of the safety, pharmacokinetics, pharmacodynamics and efficacy of veranafusp alfa in adult patients with mucopolysaccharidosis type II”, the authors discovered a technical error: figures 4 and 5 were randomly rearranged in the article relative to the captions to the figures.

Сorrect version:

The authors regret that, probably due to an oversight in the originally published version of this article, Figures 4 and 5 were rearranged relative to the captions to the figures. The error is technical in nature, it does not change the essence of the data presented in the article, but it may affect their correct perception by readers. The English version of the article is correct.

The original article in Russian has been updated in the online version: https://www.pharmpharm.ru/jour/article/view/1814